DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450)

South Korea · Delayed Price · Currency is KRW

22,750

+600 (2.71%)

Oct 2, 2026, 3:30 PM KST

Market Cap	1.03T +22.4%
Revenue (ttm)	979.60B +12.7%
Net Income	76.41B +26.9%
EPS	1,697.55 +26.3%
Shares Out	45.11M
PE Ratio	13.40
Forward PE	11.55
Dividend	200.00 (0.88%)
Ex-Dividend Date	Dec 29, 2025

Volume	750,356
Open	22,800
Previous Close	22,150
Day's Range	22,200 - 23,350
52-Week Range	16,260 - 31,250
Beta	0.01
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About DongKook Pharmaceutical

DongKook Pharmaceutical Co., Ltd. produces and sells pharmaceutical products in South Korea and internationally. The company offers non-prescription and prescription drugs, quasi drugs, medical devices, active pharmaceutical ingredients, cosmetics, and other products. Its pipeline includes DKF-MB601, used to treat Hepatitis B; DKF-MB501, to treat obesity; DKM-412 and DKM-420 to treat osteoarthritis; DKF-313, indicated for benign prostatic hyperplasia; DKF-447, to treat diabetes; DKB-123, used for wound healing, tissue repair; and DKM-428, used ... [Read more]

Industry Medical - Pharmaceuticals

Sector Healthcare

Founded 1968

Employees 1,285

Stock Exchange KOSDAQ

Ticker Symbol 086450

Full Company Profile

Financial Performance

In 2025, DongKook Pharmaceutical's revenue was 926.88 billion, an increase of 14.12% compared to the previous year's 812.17 billion. Earnings were 66.02 billion, an increase of 8.64%.

Financial Statements